A carregar...
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Combining the anti-angiogenic agent cediranib with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib improves progression-free survival compared to olaparib alone in ovarian cancer patients through an unknown mechanism. PARP inhibitors are used primarily in the treatment of patients with DNA...
Na minha lista:
| Publicado no: | Sci Transl Med |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6626544/ https://ncbi.nlm.nih.gov/pubmed/31092693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aav4508 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|